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Abstract
 
Basal cell carcinomas (BCCs) are driven by abnormal hedgehog signaling and highly overexpress
several hedgehog target genes. We report here our use of one of these target genes, hedgehog-
interacting protein (Hip1), as a tumor-associated antigen for immunoprevention of BCCs in
 
Ptch1
 
 
 
/
 
 
 
 mice treated with ionizing radiation. Hip1 mRNA is expressed in adult mouse tissues at
levels considerably lower than those in BCCs. Immunization with either of two large recombi-
nant Hip1 polypeptides was well tolerated in Ptch1
 
 
 
/
 
 
 
 mice, induced B and T cell responses
detectable by enzyme-linked immunosorbent assay, Western blot, delayed type hypersensitivity,
and enzyme-linked immunospot assay, and reduced the number of BCCs by 42% (P 
 
  
 
0.001)
and 32% (P 
 
  
 
0.01), respectively. We conclude that immunization with proteins specifically
up-regulated by hedgehog signaling may hold promise as a preventive option for patients such
as those with the basal cell nevus syndrome who are destined to develop large numbers of BCCs.
Key words: basal cell nevus syndrome • patched • skin cancer • immunization • mouse
 
Introduction
 
In the rare autosomal dominant basal cell nevus syndrome
(BCNS; Gorlin syndrome; MIM 109400) patients develop
dozens to hundreds of basal cell carcinomas (BCCs) starting
early in childhood or adolescence (1). Local growth and
treatment of the multiple tumors in these patients inevitably
causes significant scarring and disfigurement. A noninvasive,
ideally preventive therapy against BCCs would substantially
improve life quality and the management of individuals
such as those with BCNS at high risk of developing BCCs.
Since BCNS patients develop such large numbers of BCCs,
even partial prevention of tumors would provide great
clinical benefit for these patients.
Mutational activation of hedgehog signaling with over-
expression of hedgehog target genes is the pivotal step in
the development of BCCs. This activation most commonly
is effected by mutations in PTCH1, which encodes a protein
which normally inhibits hedgehog signaling, and BCNS
patients inherit one defective copy of this tumor suppressor
gene (2, 3). Among the hedgehog target genes uniformly
overexpressed in BCCs is the recently identified putative
transmembrane protein hedgehog-interacting protein (Hip1;
Hhip) (4). This consistent overexpression potentially provides
a target for immunization. As reviewed recently by Finn
and Forni, the rationale for preventive immunization
against malignancies is strong (5). When challenged before
cancer has developed, the host’s immune system has not
been impaired by tumor-induced suppression, and the
immune system may eliminate subclinical tumors much
more effectively than it can eliminate macroscopic tumors.
Indeed, recent animal studies have shown that cancer vaccines
not only are capable of protecting against tumor challenge
but also can reduce the occurrence of tumors in genetically
predisposed animals. For example, vaccination with dendritic–
tumor fusion cells prevented the development of tumors in
up to 43% of transgenic mice predisposed to develop spon-
taneous develop mammary carcinomas (6).
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Rm. 269, San Francisco, CA 94110. Phone: (415) 647-3992; Fax: (415)
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Abbreviations used in this paper:
 
 BCC, basal cell carcinoma; BCNS, basal
cell nevus syndrome; DTH, delayed-type hypersensitivity; Hip1, hedgehog-
 
interacting protein; IR, ionizing radiation;
 
 
 
ODN, oligodeoxynucleotides;
TAA, tumor-associated antigen.
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Ptch1
 
 
 
/
 
 
 
 mice, unlike previously tested mouse models
of skin carcinogenesis, develop BCCs and medulloblasto-
mas, rhabdomyosarcomas, and other phenotypic abnormal-
ities similar to those of BCNS patients (3, 7). We have
studied the Goodrich et al. model in which the lacZ and
neo genes were substituted for part of exons 1 and 2 (8).
These Ptch1
 
 
 
/
 
 
 
 mice are treated with 5 Gy ionizing radia-
tion (IR) at the age of 2 mo, all develop microscopic BCC-
like tumors by age 7 mo, and 50% of surviving individuals
develop visible BCCs by age 15 mo, making this a reliable
and practical tumor model that closely mimics human BCC
development (8).
Because Ptch1 is itself a target of hedgehog signaling, ac-
tivation of the lacZ reporter gene inserted at the Ptch1 locus
allows convenient detection of Ptch1 promotor activity and
hence of hedgehog target gene up-regulation. Consistent
with the finding of activated hedgehog signaling in human
BCCs, high levels of 
 
 
 
-galactosidase can be found in all
BCCs of Ptch1
 
 
 
/
 
 
 
 mice, whereas normal epidermis in tu-
mor-bearing mice remains negative for 
 
 
 
-galactosidase (8).
There are some hints that the immune system may help
control human BCCs. Thus, Curson and Weedon first de-
scribed the infiltration of BCCs by immune cells together
with possible signs of regression in BCCs—disruption of
the palisaded architecture of the tumor cells at the periph-
ery, occurrence of apoptotic cells, and dermal deposition
of collagen (9). Using these criteria, they found that 81 out
of 400 tumors examined had evidence of previous or con-
tinuing regression (9). Several groups have found signifi-
cantly increased numbers of CD3
 
 
 
 and CD4
 
 
 
 cells in the
tumors, and the finding of increased levels of IFN
 
 
 
mRNA in tumors suggests a possible role for CD4
 
 
 
 cells
and Th1 cytokines in the control of BCCs (10–12). Fur-
thermore, nonspecific stimulation of the immune system
by local injection of IFN
 
 
 
 or by application directly to
BCC tumors of the immune response modifier imiquimod
can reduce tumor size or even eliminate BCCs (13–17).
Postulated mechanisms for the efficacy of IFN
 
 
 
 include
the stimulation of the CD95 (Fas) receptor in the BCCs,
which in untreated patients constitutively express CD95
ligand but not the receptor. The peritumoral infiltrate
could support the resulting apoptotic suicide by the secre-
tion of IFN
 
 
 
 or IL-2, which may trigger further up-regu-
lation of CD95 on BCC cells. Imiquimod activates the
immune system through localized induction of cytokines
such as IFN
 
 
 
, IFN
 
 
 
, and IL12, and thus its mechanism of
action may be similar to that of direct cytokine treatment
with IFN
 
 
 
. Although cytokine therapy of BCCs is still ex-
perimental and its long-term efficacy has been questioned
(15), the clinical success of local immunostimulation with
IFN
 
 
 
 and imiquimod and the putative role of infiltrating
T cells in regressing BCCs have encouraged us to assess
the possibility of BCC immunoprevention using a tumor-
associated antigen.
In this study, we first investigated the expression of Hip1
mRNA in extracutaneous tissues of adult mice. Based on
our finding of the limitation of strong expression of Hip1
 
mRNA to BCCs, we immunized mice with recombinant
Hip1 fragments. We found that these peptides are immu-
nogenic and that immunization can reduce the formation
of endogenous BCCs in Ptch1
 
 
 
/
 
 
 
 mice.
 
Materials and Methods
 
Constructs and Peptides.
 
The coding sequence of pPT27, a 45-
kD His-tagged mouse Hip1 fragment (aa 147–483), was cloned
into a pRSETB (Amp) vector (Invitrogen) using EcoRI and ex-
pressed in BL21 (DE3) Gold-competent cells (Stratagene) using 1
mM IPTG (Sigma-Aldrich) for 2.5 h. Cells were lysed, and the
peptide was purified on Talon metal affinity chromatography
resin (CLONTECH Laboratories, Inc.).
pPT209, encoding a 148-aa fragment of mouse Hip1 (aa 482–
678) fused to pseudomonas exotoxin A in a pVCH6 (Amp) vec-
tor was expressed in BL21 (DE3) pLysS Gold-competent cells
(Stratagene). The resulting fusion protein was highly insoluble.
Therefore, crude bacterial lysate containing PT209 was electro-
phoresed directly on a 15% SDS page gel; the band at 85 kD was
excised, minced, homogenized in 0.85% sterile saline, and used
for injections.
 
Mice.
 
Ptch1
 
 
 
/
 
 
 
 mice were maintained at 
 
 
 
50:50 C57BL/
6.DBA/2 (B6.D2) background by continued breeding to
C57BL/6.DBA/2 F1 breeders (Jackson Labs) (8). They were fed
Purina 5008 laboratory chow and water ad libitum and were
housed in plastic cages with metal lids at 50% humidity and 70–
74
 
 
 
F with 12 h/d of white light from 34-W fluorescent bulbs. To
induce BCC formation, mice were irradiated at 8 wk (56 
 
 
 
 3 d)
with 5 Gy with a cesium-137 radiation device (half-value layer,
0.60 cm Pb, dose rate 0.94 Gy/min; Best Industries) (8).
 
 
 
-Gal Expression in Extracutaneous Tissues.
 
Tissues harvested
from 10 adult B6.D2 Ptch1
 
 
 
/
 
 
 
 mice were analyzed microscopi-
cally for lacZ expression as an indicator of hedgehog signaling
pathway activation (8).
 
Quantitative RT-PCR.
 
Hip1 expression was quantitated in
(a) commercially obtained RNA (Ambion) and (b) extracts of tis-
sues from 5 adult Ptch1
 
 
 
/
 
 
 
 B6.D2 mice. TaqMan RT-PCR
(Applied Biosystems) was performed as described, comparing the
differences in fluorescence (threshold) between tubes with
GAPDH amplification and those with the specific Hip mRNA
amplification (18).
 
Immunization.
 
Injections were started at age 11 wk, 3 wk af-
ter IR treatment: 30 mice (a) received 10 
 
 
 
g PT27 in 100 
 
 
 
l
sterile saline and ImmunEasy adjuvant (QIAGEN), a commer-
cially available mix of CpG-oligodeoxynucleotides (ODNs), pre-
pared freshly before each injection according to the manufac-
turer’s recommendation. Control groups of 30 mice each were
injected with (b) 0.85% sterile saline or (c) ImmunEasy adjuvant
in 0.85% sterile saline, respectively. A fourth study group of 17
animals was injected s.c. with 2 aliquots of 50 
 
 
 
l of a suspension
of SDS-gel slices containing (d) 10 
 
 
 
g PT209 homogenized in
sterile saline. Groups a–c mice received injections at 2-wk inter-
vals until age 32 wk; group d mice received injections every 4 wk
until age 32 wk. At age 28 wk, blood from the tail vein was as-
sessed for anti-PT27 B cell responses. A 1-cm
 
2
 
 skin biopsy was
taken from the upper back at the age of 32 wk and assessed for
BCCs with the viewer “blinded” to the treatment of the mouse
from which the skin was taken (19). After the skin biopsies, de-
layed type hypersensitivity tests (DTH) were performed on all
mice, and spleens from 10 mice per group were harvested to as-
sess in vitro T cell responses
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ELISA.
 
Costar 96-well plates (Corning Inc.) were coated
with 100 
 
 
 
g/ml PT 27 in PBS, pH 7.4. Blocking was per-
formed with 0.1% gelatin in PBS and 0.1% Tween 20 (PBS-T),
and 50 
 
 
 
l serum in PBS-T was added starting at a dilution of
1/50. Plates were developed using a phosphatase-coupled anti–
mouse antibody (Sigma-Aldrich) and p-Nitrophenyl phosphate
(Sigma-Aldrich). Absorbance was read with a 96-well plate
reader (Fisher Scientific Thermo Labsystems Multiskan MCC/
340) at 405 nm.
 
Western Blot. 
 
Samples of 400 ng PT27 were run on a 15%
SDS gel and transferred onto a PVDP membrane (E&K Scien-
tific). The membrane was cut into strips, which then were
blocked separately with 5% nonfat dry milk and incubated with
serum in blocking buffer at 1:40 dilutions. Blots were developed
using a peroxidase-coupled anti–mouse antibody (Sigma-
Aldrich) and ECL Chemiluminescence kit (Amersham Bio-
sciences). Control and test sample strips were exposed on the
same film.
 
In Vivo DTH.
 
10 
 
 
 
l of 0.85% sterile saline were injected
into the left ear pinna of each mouse, and 10 
 
 
 
l saline containing
PT27, 2 mg/ml, were injected in the pinna of the right ear using
32 G needles. The ear thickness was measured after 48 h using a
calliper (Mitoyo); DTH reactivity was expressed as the ratio be-
tween swelling of the antigen-injected site and the saline-injected
site (20).
 
ELISPOT.
 
Splenocytes (10
 
7
 
 cells/ml) from immunized mice
and from control mice were used for ELISPOT assays (21). The
mean number of spots in unstimulated wells was subtracted from
the experimental values of the stimulated cells. Data are means of
10 mice per group. Error bars represent SDs.
 
Cytokine ELISA.
 
Splenocytes (10
 
7
 
 cells/ml) from immunized
or control mice were stimulated in 24 well plates with 10 
 
 
 
g/ml
PT 27 or PBS alone, respectively. Supernatants were collected af-
ter 24 h, and capture ELISA was performed in duplicates (22).
Data are means of 10 mice per group. Error bars represent SDs.
 
Data Analysis.
 
Mean, SD, minimum, maximum, median,
and interquartile range were used to summarize the data. Because
of the small sample sizes, the Wilcoxon Rank Sum Test was used
to determine the significance of the differences between groups
(23). A box plot was used for visual description of median, range,
and interquartile range of the data (24). Statistical Software pack-
age SAS was used to perform statistical analysis.
 
Results
 
Hip1 Expression in Adult Mice.
 
Expression of hedgehog
target genes such as PTCH1, GLI1, and HIP1 is abundant
in human BCCs and BCC-like tumors of Ptch1
 
 
 
/
 
 
 
 mice.
As found previously in Ptch1
 
 
 
/
 
 
 
 mice (8), all BCCs stain
positive for 
 
 
 
-galactosidase, whereas unaffected epidermis
remains negative. Assuming that 
 
 
 
-galactosidase activity
would be detectable in all tissues with strong expression of
hedgehog target genes, we autopsied 10 adult Ptch1
 
 
 
/
 
 
 
mice, which had received 5 Gy Cs
 
137
 
 ionizing radiation at
the age of 2 mo and which, at the time of the biopsy, had
multiple macroscopic and numerous microscopic BCCs,
and we examined tissue from major organs for 
 
 
 
-galactosi-
dase staining. These extracutaneous tissues had no 
 
 
 
-gal
staining except for occasional very small stromal foci in
sections of the bladder, the ovary, and the cecum (Fig. 1).
To verify that lack of transcriptional activation of the lacZ
gene at the Ptch1 locus correlates with minimal to no ex-
pression of Hip1 in extracutaneous tissues, we assayed the
level of Hip1 mRNA in extracts of adult Ptch1
 
 
 
/
 
 
 
 mouse
tissues and in commercially available standard RNA from
various Ptch1
 
 
 
/
 
 
 
 wild-type mouse tissues. We detected
expression of the Hip1 transcript in all tissues examined ex-
Figure 1.  -Galactosidase stain-
ing for hedgehog signaling dysreg-
ulation in adult mouse tissues.
Histological sections of organs
obtained from 10–15-mo-old
tumor-bearing Ptch1 /  mice
after treatment with 5 Gy ionizing
radiation at the age of 2 mo.
Sections were stained for  -galac-
tosidase expression. Except for a
few stromal foci in cecum, ovary,
and bladder of some animals,
BCCs were the only adult tissue
with strong activation of hedge-
hog signaling, indicating tumor-
specific up-regulation of hedgehog
target genes. Arrows indicate
positive staining for  -galactosi-
dase. Brain (A), thymus (B), pan-
creas/spleen (C), liver (D), lung
(E), heart (F), kidney (G), bladder
(H), testis (I), ovary (J), cecum
(K), and skin with microscopic
BCCs (L).
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cept heart, but Hip1 mRNA levels were up to 150-fold
higher in BCCs than in normal tissue (Table I). Our data
suggest that Hip1 is expressed at much higher levels in
BCCs than elsewhere in IR-treated adult Ptch1
 
 
 
/
 
 
 
 mice.
The level of Hip1 mRNA in embryonic tissue was compa-
rable to its levels in some BCCs, which is consistent with
the important role of hedgehog signaling in early develop-
ment (Table I).
 
Induction of Anti-Hip1 Immune Reactivity.
 
Thus, having
identified Hip1 as a tumor-associated antigen in mice and
humans we next assessed whether it would be possible to
induce immune responses against recombinant fragments of
Hip1 and whether the administration of the peptides to
Ptch1
 
 
 
/
 
 
 
 mice would protect against tumor growth.
Our study included three main groups of mice: those re-
ceiving injections with (a) sterile saline, (b) CpG-ODNs,
or (c) CpG-ODNs in combination with the recombinant
Hip1 fragment PT27 (Fig. 2). A fourth study group re-
ceived monthly injections of the highly insoluble Hip1-
pseudomonas exotoxin A fusion protein PT209 in SDS-
PAGE gel without additional adjuvant. Injections were
well tolerated by all test animals. We observed no local (at
injection sites) or systemic (as judged by changes in behav-
ior or weight gain) toxicity in immunized mice. No change
in hair coat was seen. At the age of 32 wk when the skin
biopsies were taken, 92% of the saline-injected control
group and 89% of the mice receiving CpG-ODNs, PT27,
or PT209 were still alive.
Animals immunized with PT27 
 
  
 
CpG developed
strong antibody responses to PT27 as detected by ELISA
(Fig. 3 A). Consistent with this finding, sera from mice re-
ceiving PT27 injections bound strongly to PT27 peptide
on Western blots (Fig. 3 C). Mice injected with PT27 
 
 
 
CpG also developed strong cell-mediated immune re-
sponses as detected by ELISPOT assay (Fig. 4 A). Spleen
cells from immunized mice were assayed for their ability to
secrete IFN
 
 
 
 during in vitro stimulation with the polypep-
tide PT27, which had been used for the immunization.
Figure 3. Antibody response to Hip1 immunization. (A) ELISAs were
performed on PT27-coated plates using sera from mice receiving sterile
saline, CpG in sterile saline, or PT27   CpG in sterile saline at a dilution
of 1:200. (B) Purified PT27 (1 mg/ml) on a 15% SDS polyacrylamide gel.
(C) To confirm the specificity of the antibodies, Western blots were per-
formed using sera from mice receiving sterile saline, CpG in sterile saline,
or PT27   CpG in sterile saline at a dilution of 1:40 on purified PT27
(400 ng). Each of the three lanes in the two blots are the assessment of
serum from an individual mouse.
 
Table I.
 
Expression of Hip1 mRNA in Adult Mouse Tissues
 
Tissue
 
 
 
CT standard RNA 
(Ambion)
 
a
 
Adult Ptch1
 
 
 
/
 
 
 
 mice
(pooled for five adult animals)
Liver 9.6 8.3
Lung 7.1 8.1
Spleen 13.2 10.1
Heart ND 14.0
Brain 9.3 5.0
Ovary 8.8 8.1
Textix 9.6 8.0
Embryo 5.0 -
Thymus 10.2 9.0
Intestine - 8.7
BCC-1
 
b
 
1.8
BCC-2 3.4
BCC-3 4.0
 
a
 
mRNA levels were measured by Taqman analysis using primers and
probes specific for Hip1 and normalized to the expression level of
GAPDH.  Values are expressed as 
 
 
 
CT.
 
b
 
BCC-1, -2, and -3 were individual tumors rather than pooled samples.
Figure 2. Injection schedule. All mice received 5 Gy
ionizing radiation at the age of 8 wk; the injections were
started at the age of 11 wk. Mice received 0.85% sterile saline,
0.85% sterile saline, and CpG or the recombinant polypeptide
PT27 with CpG in 0.85% sterile saline s.c. every 2 wk. A
fourth group of mice received s.c. injections of suspensions
of recombinant polypeptide PT209 in SDS-PAGE gel in
0.85% sterile saline every 4 wk. At the age of 24 wk, sera
were tested for antibody responses with ELISA and Western blot. 1-cm2 biopsies were taken at the age of 32 wk. At 36 wk, DTH assays were performed
on all study mice. After the DTH assessment, spleens from 10 mice per group were harvested for ELISPOT assays and ELISAs in order to assess peptide-
specific T cell responses.
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immunized with PT209. We further compared the PT27
and PT209 results against those of the controls. Mice in-
jected with CpG-ODN had a median of 10 BCCs and
0.0572 BCC burden. Mice injected with PT27 and CpG  
ODN had a median of 5 BCCs and 0.0219 BCC burden.
Mice injected with saline control had a median of 11
BCCs and 0.0682 BCC burden. Mice injected with
PT209 had a median of 7 BCCs and 0.0348 BCC burden.
p-values between CpG-ODN vs. CPG-ODN   PT27 were
 0.001 for BCC number, 0.005 for burden, and not sig-
Table II. Descriptive Statistics of the Number, Area, and Burden of Microscopic BCC (1-cm2 Skin Biopsies) Per Animal at the Age of 8 Mo
Treatments
BCC parameters Control PT209 CpG-ODN CpG-ODN + PT27
p-valuea for 
treatment differences
(n   19) (n   17) (n   22) (n   23)
Lesion number
Median (range) 11 (5–17) 7 (1–16) 10 (3–18) 5 (1–13)  0.001
  Mean (SD)  10.7 (3.07) 7.29 (4.21) 10.46 (3.53) 6 (3.16)
Lesion area
  Median (range) 0.0055
(0.003–0.023)
0.0052
(0.0023–0.0112)
0.0066
(0.001–0.0261)
0.0045
(0.0255–0.0263) 0.37
  Mean (SD) 0.0087 (0.0056) 0.006 (0.0028) 0.0085 (0.0065) 0.0069 (0.0061)
Lesion burden
  Median (range) 0.0682
(0.0227–0.02649)
0.0348
(0.0024–0.1788)
0.0572
(0.003–0.3034)
0.0219
(0.0045–0.3423) 0.07
  Mean (SD) 0.097 (0.0733) 0.0514 (0.048) 0.0957 (0.0827) 0.0535 (0.0778)
ap-value was calculated by the Wilcoxon Rank Sum Test.
Table III. Three Pairwise Comparisons for BCC Number, Area, 
and Burden Using Wilcoxon Rank Sum Test
BCC
Comparisons Parameters p-value
Saline vs. CpG-ODN Number 0.65
Area 0.99
Burden 0.87
Saline vs. PT209 Number 0.008
Area 0.15
Burden 0.019
CpG-ODN vs. CPG-ODN   PT27 Number <0.001
Area 0.24
Burden 0.005
CPG-ODN   PT27 vs. PT209 Number 0.35
Area 0.67
Burden 0.39
Mice receiving the peptide injections had a threefold in-
crease in spots per well (Fig. 4 A). The findings in the
ELISPOT assays were confirmed with capture ELISA of
supernatants from splenocyte cultures exposed to PT27 for
24 h. The concentration of IFN  supernatant in culture
media 24 h after restimulation of spleen cells was increased
2.1–2.8-fold compared with the groups that received sterile
saline or CpG-ODNs only (Fig. 4 B).
To investigate in vivo cell-based immune responses, we
used the DTH skin reaction to detect antigen-specific im-
munity. 19 of 23 peptide-injected animals developed an
erythematous induration at the injection site of the pep-
tide-injected ear pinna. In contrast, no DTH reaction was
observed in control mice. The average ear thickness index,
the thickness of the peptide-injected ear pinna compared
with the water-injected side, was significantly higher in test
animals than in the control groups: 1.79 versus 1.07 for sa-
line-injected and 1.04 for CpG-injected.
Inhibition of Tumorigenesis in Immunized Mice (Fig. 5).
Table II summarizes the BCC data and the p-values for
simultaneous comparisons of all treatment differences.
There were significant differences between the four treat-
ment groups in lesion numbers (P   0.001), marginally
significant reductions in tumor burden (P   0.07), and no
statistically significant differences in BCC area (P   0.37).
Table III shows the significance results of pairwise com-
parisons between groups for BCC number, area, and bur-
den. The Wilcoxon Rank Sum Test confirms that there
was no difference in BCCs between mice injected with sa-
line (Table II, Control) and mice injected with the adju-
vant (Table II, CpG-ODN) in the BCC number, area,
and burden. Neither were there significant differences be-
tween BCCs in mice immunized with PT27 versus those
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nificant for BCC area; between PT209 and saline controls
were 0.008 for BCC number, 0.019 for burden, and not
significant for BCC area.
Discussion
The identification of the mutations causing BCNS al-
lows the early identification of affected individuals. In a
study of 90 Caucasian BCNS patients, 80% had at least one
BCC, and the number of BCCs ranged from 1 to  1,000
(25). Their continued accumulation of BCCs makes assess-
ment of preventive agents highly feasible and clinically im-
portant. Vaccination with a tumor antigen could be an
ideal method to reduce or even prevent tumor formation
in these individuals. The recently published reduction of
the incidence of HPV-16 infection and of HPV-16–related
cervical intraepithelial neoplasia in a study of 2,392 young
women receiving HPV-16 virus-like particle vaccine dem-
onstrates the great potential of antitumor vaccines, al-
though the target in this study was an infectious agent
which causes tumors rather than a TAA (26). Direct vacci-
nation with tumor-associated antigens, as performed in our
study, extends this traditional concept of vaccination to en-
dogenously forming tumors.
BCCs are comparatively homogenous tumors. Genetic
instability of BCCs appears to be much less than that of
most other tumors, and metastasis is rare. Thus, one study
found aneuploidy in 19% of 509 BCCs compared with 75%
in other solid tumors (27). Allelic deletions on chromosome
9 at the patched gene locus are characteristic for BCCs, but
deletions are uncommon at other chromosomal sites. Ac-
cordingly, Quinn et al. found loss of heterozygosity of one
or more 9q markers in 33 of 44 BCCs (28). In animal mod-
els, mutational activation of hedgehog signaling is sufficient
to induce BCC-like lesions, and mutations in PTCH1 and/
or SMO, both components of the hedgehog signaling cas-
cade, have been found in  90% of human BCCs (29–31).
This characteristic defect of BCCs led us to investigate fur-
ther the expression of the hedgehog target gene Hip1 as a
possible candidate for future immunization studies.
In our study of various tissues of Ptch1 /  mice, quanti-
tative real-time RT-PCR identified basal expression of
Hip1 mRNA in all tissues examined except heart tissue.
These results are in accordance with reports by Bak et al.
who found expression of human Hip1 in fetal and adult hu-
man tissues except fetal ovary (32). Nonetheless, with up to
150-fold higher mRNA levels in BCCs than in normal skin
and other organs, Hip1 appears to be up-regulated in adult
mice specifically in BCCs and therefore may be a suitable
target for vaccination strategies. Most identified human tu-
mor-associated antigens (TAAs) are “self-antigens” with
some expression in normal adult tissue. Carcinoembryonic
antigen, for example, is a TAA which is overexpressed in
various carcinomas including gastrointestinal carcinomas
but also is expressed in normal colonic mucosa (33). Simi-
larly tyrosinase-related protein 2 (34) and the HER-2/neu
(35) antigen are expressed not only on cancerous cells but
also on normal tissue, and in some cases successful rejection
of established tumors could be achieved only in the pres-
ence of severe autoimmune responses (36). However anti-
tumor responses against other normal differentiation anti-
gens can be generated with little evidence for destructive
autoimmunity (37–39). Consistent with these latter reports,
injections of Hip1 polypeptides were well tolerated in our
study and yet induced peptide-specific immune responses.
Although expression of hedgehog target genes has been re-
ported in the bulge region of the adult hair follicle in hu-
mans and in mice and although involvement of hedgehog
signaling in the regulation of the adult hair cycle has been
proposed (40–42), no gross change in hair was seen in im-
munized Ptch1 /  mice. Because hedgehog signaling is im-
portant in embryonic development, we assumed that the
antigenicity of Hip1 would be low and that immunization
against Hip1 would require the coadministration of adju-
vants. In rodents and humans, CpG-ODNs stimulate the
expression of Th1-like cytokines and of costimulatory mol-
ecules and lead to a general increase in antigen-presenting
function (43). If used as adjuvant, CpG-ODNs give potent
antibody and CTL responses. In a recently published paper,
Figure 4. T cell response to Hip1 immunization. (A) T cell responses
were assayed in vitro with ELISPOT assays. 5   105 isolate spleen cells
were pulsed with the recombinant Hip1 fragment PT27. After overnight
incubation at 37 C and 5% CO2, the wells were washed and the number
of IFN  spots revealed as described in Materials and Methods. (B) The
data were confirmed by ELISA on culture supernatant of isolate spleen
cells stimulated with 10  g/ml PT27 for 24 h.
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Kim et al. demonstrated that immunization of C57BL/6
mice with the HPV oncogenic proteins E6 and E7 in com-
bination with CpG-ODNs significantly reduced growth of
HPV-driven tumor cells not only when administered be-
fore but even after murine tumors had developed (44). In
some animal models, even monotherapy with peritumoral
CpG-ODN injections enhanced antitumor immunity with
rejection of established tumors at the injection site and at
distant sites (45). CpG-ODNs are not immunogenic and
unlike Freund’s adjuvant do not cause granulomatous reac-
tions. Therefore, they can be injected repetitively without
severe side effects (46, 47). In our study, the repetitive ad-
ministration of PT27 in combination with CpG-ODNs
was sufficient to overcome the self-tolerance expected due
to high-level expression of Hip1 during development and
low-level expression in adult tissues.
We found strong PT27-specific antibody responses in
PT27-injected mice, and this peptide also induces anti-Hip1
antibodies in rabbits (unpublished data). The exact localiza-
tion of Hip1 within the cells remains unclear, and its immu-
nogenic properties so far have not been investigated in de-
tail. Yet, as a putative transmembrane protein, Hip1 might
well be accessible to antibody binding. In other cancer
models antitumor antibodies have been shown to mediate
anti-tumor effects effectively. Antitumor activities of the re-
cently approved therapeutic antibodies Trastuzumab (Her-
ceptin), specific for the protooncogene p185HER-2/neu in
breast cancer, and Rituximab (Rituxan), a monoclonal
Figure 5. At the age of 32 wk, 1-cm2
skin biopsies were taken from each animal.
The median number of microscopic BCC
per animal (A), the median cross-sectional
area of tumors in each sample (B), and the
median total tumor burden per animal (C)
were determined microscopically. Each rect-
angular  box indicates interquartile range
(25% and 75% percentiles) with median inside
the box and average as shown with  . The
highest and lowest bars are the maximum
and minimum values. Statistical analysis using
the Wilcoxon Rank Sum Test showed a
significant reduction of tumor number in
mice immunized with CpG-ODN   PT27
and in mice immunized with the fusion
protein PT209 against control groups (A); a
significant reduction of tumor burden in
mice with PT27   CpG and in mice with
PT209 against controls (C). There were no
significant differences of BCC number,
area, and burden either between Control
and CpG-ODN or between CpG-ODN  
PT27 and PT209.
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IgG1 specific for the B cell marker CD20, prove that antitu-
mor antibodies can be a powerful tool in cancer therapy.
Spleen cells from PT27-injected Ptch1 /  mice pro-
duced significantly more IFN  in response to in vitro stim-
ulation with the recombinant Hip1 peptide PT27 than did
spleen cells from control mice receiving saline or CpG in-
jections. Moreover, 19 out of 23 peptide-injected mice de-
veloped DTH. Detailed immunology-focused studies will
help to elucidate further the immunological properties of
Hip1 and to optimise future immunization strategies. Cen-
tral to our study is the more general observation that Hip1
injections were well tolerated and induced detectable B cell
and T cell responses and that these findings may be of clin-
ical relevance because Hip1-injected mice developed sig-
nificantly fewer microscopic tumors than did control mice.
This is to our knowledge the first attempt to immunize
against BCCs, and therefore we consider the partial reduc-
tion of microscopic tumors with two different peptides to
be a very encouraging result. For BCNS patients and others
developing many BCCs, even a partial reduction of tumors
would substantially improve their quality of life.
In summary, we have defined Hip1 as a tumor-associ-
ated protein and presented evidence that immunization
against BCCs with recombinant fragments of Hip1 induced
immune responses despite the “self-nature” of this protein.
Moreover, injection of two different Hip1 polypeptides in
two different test groups led to a significant reduction of
microscopic tumors in the peptide-injected mice compared
with saline- and adjuvant-injected animals. Based on these
data, we believe that Hip1 is a suitable molecule for further
studies in this field. Ptch1 /  mice present a valuable
model for the investigation of therapies against BCCs be-
cause the mice develop endogenous BCCs, closely mim-
icking the course of disease in high-risk individuals such as
BCNS patients. Future studies will focus on the immunol-
ogy of Hip1 and other proteins which are up-regulated by
hedgehog signaling and on why some tumors appear to
have escaped the immune response.
We thank T. Kornberg and members of his lab for assistance with
expression of recombinant Hip1, B. Grant and J. Kropp for assis-
tance with the TaqMan RT-PCR, K. Chu for IR administration,
D. Nixon for sharing his ELISPOT reader, J. Hwang and Y. Lu for
assistance with the statistical analysis, and L. Lanier for helpful dis-
cussions. We gratefully thank the Michael J. Rainen Family Foun-
dation and Patricia Hughes for their generous support.
A. Vogt was a fellow of the Deutsche Forschungsgemeinschaft.
This study was supported by a grant from the National Institutes of
Health (U19 CA81888).
Submitted: 17 July 2003
Accepted: 21 January 2004
References
1. Gorlin, R.J. 1987. Nevoid basal-cell carcinoma syndrome.
Medicine (Baltimore). 66:98–113.
2. Johnson, R.L., A.L. Rothman, J. Xie, L.V. Goodrich, J.W.
Bare, J.M. Bonifas, A.G. Quinn, R.M. Myers, D.R. Cox,
E.H. Epstein, Jr., and M.P. Scott. 1996. Human homolog of
patched, a candidate gene for the basal cell nevus syndrome.
Science. 272:1668–1671.
3. Hahn, H., C. Wicking, P.G. Zaphiropoulos, M.R. Gailani,
S. Shanley, A. Chidambaram, I. Vorechovsky, E. Holmberg,
A.B. Unden, S. Gillies, et al. 1996. Mutations of the human
homologue of Drosophila patched in the nevoid basal cell car-
cinoma syndrome. Cell. 85:841–851.
4. Chuang, P.T., and A.P. McMahon. 1999. Vertebrate Hedge-
hog signalling modulated by induction of a Hedgehog-bind-
ing protein. Nature. 397:617–621.
5. Finn, O.J., and G. Forni. 2002. Prophylactic cancer vaccines.
Curr. Opin. Immunol. 14:172–177.
6. Xia, J., Y. Tanaka, S. Koido, C. Liu, P. Mukherjee, S.J. Gend-
ler, and J. Gong. 2003. Prevention of spontaneous breast car-
cinoma by prophylactic vaccination with dendritic/tumor fu-
sion cells. J. Immunol. 170:1980–1986.
7. Goodrich, L.V., L. Milenkovic, K.M. Higgins, and M.P.
Scott. 1997. Altered neural cell fates and medulloblastoma in
mouse patched mutants. Science. 277:1109–1113.
8. Aszterbaum, M., J. Epstein, A. Oro, V. Douglas, P.E. LeBoit,
M.P. Scott, and E.H. Epstein, Jr. 1999. Ultraviolet and ionizing
radiation enhance the growth of BCCs and trichoblastomas in
patched heterozygous knockout mice. Nat. Med. 5:1285–1291.
9. Curson, C., and D. Weedon. 1979. Spontaneous regression
in basal cell carcinomas. J. Cutan. Pathol. 6:432–437.
10. Nguyen, Q.H., R.L. Moy, M.D. Roth, R. Yamamoto, S.
Tomono, and S.M. Dubinett. 1993. Expression of CD45 iso-
forms in fresh and IL-2-cultured tumor-infiltrating lympho-
cytes from basal cell carcinoma. Cell. Immunol. 146:421–430.
11. Guillen, F.J., C.L. Day, Jr., and G.F. Murphy. 1985. Expres-
sion of activation antigens by T cells infiltrating basal cell car-
cinomas. J. Invest. Dermatol. 85:203–206.
12. Wong, D.A., G.A. Bishop, M.A. Lowes, B. Cooke, R.S.
Barnetson, and G.M. Halliday. 2000. Cytokine profiles in
spontaneously regressing basal cell carcinomas. Br. J. Derma-
tol. 143:91–98.
13. Beutner, K.R. 2000. Imiquimod–clinical efficacy. Ann. Der-
matol. Venereol. 127:3S19–3S21.
14. Buechner, S.A., M. Wernli, T. Harr, S. Hahn, P. Itin, and P.
Erb. 1997. Regression of basal cell carcinoma by intralesional
interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-
CD95 ligand-induced suicide. J. Clin. Invest. 100:2691–2696.
15. Cornell, R.C., H.T. Greenway, S.B. Tucker, L. Edwards, S.
Ashworth, J.C. Vance, D.J. Tanner, E.L. Taylor, K.A.
Smiles, and E.A. Peets. 1990. Intralesional interferon therapy
for basal cell carcinoma. J. Am. Acad. Dermatol. 23:694–700.
16. Geisse, J.K., P. Rich, A. Pandya, K. Gross, K. Andres, A.
Ginkel, and M. Owens. 2002. Imiquimod 5% cream for the
treatment of superficial basal cell carcinoma: a double-blind,
randomized, vehicle-controlled study. J. Am. Acad. Dermatol.
47:390–398.
17. Marks, R., K. Gebauer, S. Shumack, M. Amies, J. Bryden,
T.L. Fox, and M.L. Owens. 2001. Imiquimod 5% cream in
the treatment of superficial basal cell carcinoma: results of a
multicenter 6-week dose–response trial. J. Am. Acad. Derma-
tol. 44:807–813.
18. Hu, Z., J.M. Bonifas, G. Aragon, L. Kopelovich, Y. Liang, S.
Ohta, M.A. Israel, D.R. Bickers, M. Aszterbaum, and E.H.
Epstein, Jr. 2003. Evidence for lack of enhanced hedgehog
target gene expression in common extracutaneous tumors.
Cancer Res. 63:923–928.
19. Hebert, J.L., F. Khugyani, M. Athar, L. Kopelovich, E.H.
 
o
n
 
A
u
g
u
s
t
 
1
8
,
 
2
0
0
6
 
w
w
w
.
j
e
m
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 Vogt et al. 761
Epstein, Jr., and M. Aszterbaum. 2001. Chemoprevention of
basal cell carcinomas in the ptc1 /  mouse–green and black
tea. Skin Pharmacol. Appl. Skin Physiol. 14:358–362.
20. Berden, J.H., P. Faaber, K.J. Assmann, and T.P. Rijke. 1986.
Effects of cyclosporin A on autoimmune disease in MRL/1
and BXSB mice. Scand. J. Immunol. 24:405–411.
21. Carvalho, L.H., J.C. Hafalla, and F. Zavala. 2001. ELISPOT
assay to measure antigen-specific murine CD8( ) T cell re-
sponses. J. Immunol. Methods. 252:207–218.
22. Ekerfelt, C., J. Ernerudh, and M.C. Jenmalm. 2002. Detec-
tion of spontaneous and antigen-induced human interleukin-4
responses in vitro: comparison of ELISPOT, a novel ELISA
and real-time RT-PCR. J. Immunol. Methods. 260:55–67.
23. Rosner, B. 1995. Fundamentals of Biostatistics. Duxbury
Press, Belmont, CA. 682 pp.
24. Tukey, J.W. 1977. Exploratory Data Analysis. Addison-Wes-
ley Publishing Co., Reading, MA. 688 pp.
25. Kimonis, V.E., A.M. Goldstein, B. Pastakia, M.L. Yang, R.
Kase, J.J. DiGiovanna, A.E. Bale, and S.J. Bale. 1997. Clini-
cal manifestations in 105 persons with nevoid basal cell carci-
noma syndrome. Am. J. Med. Genet. 69:299–308.
26. Koutsky, L.A., K.A. Ault, C.M. Wheeler, D.R. Brown, E.
Barr, F.B. Alvarez, L.M. Chiacchierini, and K.U. Jansen.
2002. A controlled trial of a human papillomavirus type 16
vaccine. N. Engl. J. Med. 347:1645–1651.
27. Barlogie, B., M.N. Raber, J. Schumann, T.S. Johnson, B.
Drewinko, D.E. Swartzendruber, W. Gohde, M. Andreeff,
and E.J. Freireich. 1983. Flow cytometry in clinical cancer
research. Cancer Res. 43:3982–3997.
28. Quinn, A.G., S. Sikkink, and J.L. Rees. 1994. Delineation of
two distinct deleted regions on chromosome 9 in human non-
melanoma skin cancers. Genes Chromosomes Cancer. 11:222–225.
29. Dahmane, N., J. Lee, P. Robins, P. Heller, and A. Ruiz i Al-
taba. 1997. Activation of the transcription factor Gli1 and the
Sonic hedgehog signalling pathway in skin tumours. Nature.
389:876–881.
30. Ling, G., A. Ahmadian, A. Persson, A.B. Unden, G. Afink, C.
Williams, M. Uhlen, R. Toftgard, J. Lundeberg, and F.
Ponten. 2001. PATCHED and p53 gene alterations in spo-
radic and hereditary basal cell cancer. Oncogene. 20:7770–7778.
31. Xie, J., M. Murone, S.M. Luoh, A. Ryan, Q. Gu, C. Zhang,
J.M. Bonifas, C.W. Lam, M. Hynes, A. Goddard, et al. 1998.
Activating Smoothened mutations in sporadic basal-cell car-
cinoma. Nature. 391:90–92.
32. Bak, M., C. Hansen, K. Friis Henriksen, and N. Tommerup.
2001. The human hedgehog-interacting protein gene: struc-
ture and chromosome mapping to 4q31.21→q31.3. Cytoge-
net. Cell Genet. 92:300–303.
33. Guadagni, F., M. Roselli, M. Cosimelli, A. Spila, F. Cava-
liere, R. Arcuri, R. D’Alessandro, P.L. Fracasso, V. Casale,
A. Vecchione, et al. 1997. Quantitative analysis of CEA ex-
pression in colorectal adenocarcinoma and serum: lack of
correlation. Int. J. Cancer. 72:949–954.
34. Wang, R.F., E. Appella, Y. Kawakami, X. Kang, and S.A.
Rosenberg. 1996. Identification of TRP-2 as a human tumor
antigen recognized by cytotoxic T lymphocytes. J. Exp. Med.
184:2207–2216.
35. Peoples, G.E., P.S. Goedegebuure, R. Smith, D.C. Linehan,
I. Yoshino, and T.J. Eberlein. 1995. Breast and ovarian can-
cer-specific cytotoxic T lymphocytes recognize the same
HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA. 92:
432–436.
36. Ludewig, B., A.F. Ochsenbein, B. Odermatt, D. Paulin, H.
Hengartner, and R.M. Zinkernagel. 2000. Immunotherapy
with dendritic cells directed against tumor antigens shared
with normal host cells results in severe autoimmune disease.
J. Exp. Med. 191:795–804.
37. Morgan, D.J., H.T. Kreuwel, S. Fleck, H.I. Levitsky, D.M.
Pardoll, and L.A. Sherman. 1998. Activation of low avidity
CTL specific for a self epitope results in tumor rejection but
not autoimmunity. J. Immunol. 160:643–651.
38. Naftzger, C., Y. Takechi, H. Kohda, I. Hara, S. Vijayasara-
dhi, and A.N. Houghton. 1996. Immune response to a dif-
ferentiation antigen induced by altered antigen: a study of tu-
mor rejection and autoimmunity. Proc. Natl. Acad. Sci. USA.
93:14809–14814.
39. Overwijk, W.W., D.S. Lee, D.R. Surman, K.R. Irvine, C.E.
Touloukian, C.C. Chan, M.W. Carroll, B. Moss, S.A.
Rosenberg, and N.P. Restifo. 1999. Vaccination with a re-
combinant vaccinia virus encoding a “self” antigen induces
autoimmune vitiligo and tumor cell destruction in mice: re-
quirement for CD4( ) T lymphocytes. Proc. Natl. Acad. Sci.
USA. 96:2982–2987.
40. Ghali, L., S.T. Wong, J. Green, N. Tidman, and A.G.
Quinn. 1999. Gli1 protein is expressed in basal cell carcino-
mas, outer root sheath keratinocytes and a subpopulation of
mesenchymal cells in normal human skin. J. Invest. Dermatol.
113:595–599.
41. Sato, N., P.L. Leopold, and R.G. Crystal. 1999. Induction of
the hair growth phase in postnatal mice by localized transient
expression of Sonic hedgehog. J. Clin. Invest. 104:855–864.
42. Sato, N., P.L. Leopold, and R.G. Crystal. 2001. Effect of
adenovirus-mediated expression of Sonic hedgehog gene on
hair regrowth in mice with chemotherapy-induced alopecia.
J. Natl. Cancer Inst. 93:1858–1864.
43. Krieg, A.M. 2002. CpG motifs in bacterial DNA and their
immune effects. Annu. Rev. Immunol. 20:709–760.
44. Kim, T.Y., H.J. Myoung, J.H. Kim, I.S. Moon, T.G. Kim,
W.S. Ahn, and J.I. Sin. 2002. Both E7 and CpG-oligodeoxy-
nucleotide are required for protective immunity against chal-
lenge with human papillomavirus 16 (E6/E7) immortalized
tumor cells: involvement of CD4  and CD8  T cells in
protection. Cancer Res. 62:7234–7240.
45. Heckelsmiller, K., K. Rall, S. Beck, A. Schlamp, J. Seiderer,
B. Jahrsdorfer, A. Krug, S. Rothenfusser, S. Endres, and G.
Hartmann. 2002. Peritumoral CpG DNA elicits a coordi-
nated response of CD8 T cells and innate effectors to cure es-
tablished tumors in a murine colon carcinoma model. J. Im-
munol. 169:3892–3899.
46. Lipford, G.B., T. Sparwasser, S. Zimmermann, K. Heeg, and
H. Wagner. 2000. CpG-DNA-mediated transient lymphade-
nopathy is associated with a state of Th1 predisposition to an-
tigen-driven responses. J. Immunol. 165:1228–1235.
47. Krieg, A.M., and H.L. Davis. 2001. Enhancing vaccines with
immune stimulatory CpG DNA. Curr. Opin. Mol. Ther.
3:15–24.
 
o
n
 
A
u
g
u
s
t
 
1
8
,
 
2
0
0
6
 
w
w
w
.
j
e
m
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 